MiMedx price target lowered to $6 from $7 at Citizens

Citizens lowered the firm’s price target on MiMedx (MDXG) to $6 from $7 and keeps an Outperform rating on the shares. MiMedx is navigating a difficult 2026 transition year due to Medicare reimbursement changes that have pressured pricing and disrupted ordering patterns, leading to weaker-than-expected sales and a reduced annual outlook, the analyst tells investors in a reserch note. These headwinds are viewed as temporary, with unaffected segments providing stability and potential for recovery once demand normalizes, the firm says.